Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575474 | 1.00 | OPRD1 (0.80) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4576345 | 1.00 | OPRD1 (0.80) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6935573 | 1.00 | OPRD1 (0.80) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4575611 | 1.00 | OPRD1 (0.80) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6935549 | 1.00 | OPRD1 (0.80) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6933759 | 0.92 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL9540197 | 0.92 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6933756 | 0.92 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL6933758 | 0.92 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL9540201 | 0.92 | OPRD1 (0.72) | OPRD1CYP1A2CYP3A4CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | claimed |
| EP-0649414-B1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | ARDENT PHARMACEUTICALS INC (US) | 2003-04-16 | — | — | EP | claimed |
| US-20020111359-A1 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2002-08-15 | — | — | US | claimed |
| US-6300332-B1 | DRUG MEDIATED RESPIRATORY DEPRESSION, MUSCLE RIGIDITY AND NAUSEA/VOMITING AND SIDE EFFECT REDUCTION | DELTA PHARMACEUTICALS, INC. | 2001-10-09 | — | — | US | claimed |
| EP-1003373-A4 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS INC (US) | 2000-09-20 | — | — | EP | claimed |
| EP-0938317-A4 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS INC (US) | 2000-08-23 | — | — | EP | claimed |
| EP-1003373-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0938317-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | claimed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | claimed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | claimed |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | ENTA HOLDING LLC | 2008-08-14 | — | — | US | disclosed |
| US-20050255151-A1 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | ENTA HOLDING LLC | 2005-11-17 | — | — | US | disclosed |
| US-6919350-B2 | Side effect reduction of narcotics | ARDENT PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-0938317-B1 | COMPOSITIONS FOR REDUCING RESPIRATORY DEPRESSION | ARDENT PHARMACEUTICALS INC (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-1999001033-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | DELTA PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1997046240-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION | DELTA PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0649414-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993015062-A1 | OPIOID DIARYLMETHYLPIPERAZINES AND PIPERIDINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050255151-A1 | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 751/4885CYP3A4 866/4885 |
| US-20020111359-A1 | Side effect reduction of narcotics | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 758/4885CYP3A4 814/4885 |
| US-20080193383-A1 | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION AND ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885CYP1A2 751/4885CYP3A4 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.